As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues thanks in large part to the performance of eye disease drug Vabysmo.Despite losing 4.3 billion Swiss francs (CHF) in COVID-related revenues across its diagnostics […]
